OPRM1, opioid receptor mu 1, 4988

N. diseases: 370; N. variants: 42
Disease: Neuralgia ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0027796
Disease: Neuralgia
Neuralgia 		0.400 Biomarker phenotype BEFREE PERSPECTIVE: This study demonstrates that a MOR-DOR dual agonist given chronically in chronic neuropathic pain models has enhanced efficacy with strongly reduced tolerance and dependence, with a further anti-inflammatory effect in the spinal cord. 31201990 2019
CUI: C0027796
Disease: Neuralgia
Neuralgia 		0.400 Biomarker phenotype BEFREE We further show that the inhibitory function of MOR is impaired during neuropathic pain. 31316354 2019
CUI: C0027796
Disease: Neuralgia
Neuralgia 		0.400 PosttranslationalModification phenotype BEFREE These findings indicate that OCT1 may participate in neuropathic pain at least in part by transcriptionally activating Dnmt3a and subsequently epigenetic silencing of Oprm1 and Kcan2 in the DRG. 30247265 2019
CUI: C0027796
Disease: Neuralgia
Neuralgia 		0.400 AlteredExpression phenotype BEFREE These findings suggest that DRG TET1 overexpression mitigated neuropathic pain likely through rescue of MOR and Kv1.2 expression in the ipsilateral DRG. 30515739 2019
CUI: C0027796
Disease: Neuralgia
Neuralgia 		0.400 Biomarker phenotype BEFREE Moreover, evidences of neuroplastic changes that may underlie the low efficacy of MOR agonists under neuropathic pain conditions are reviewed and discussed. 30318675 2019
CUI: C0027796
Disease: Neuralgia
Neuralgia 		0.400 Biomarker phenotype BEFREE Agonists selectively acting at NOP, MOP, DOP and KOP receptors as well as mixed opioid receptor agonists are known to exert anti-hypersensitive efficacy in the rat spinal nerve ligation (SNL) model of neuropathic pain. 29524385 2018
CUI: C0027796
Disease: Neuralgia
Neuralgia 		0.400 GeneticVariation phenotype BEFREE In the meta-analysis, polymorphisms in HLA-DRB1*13 (odds ratio [OR], 2.96; confidence interval [CI], 1.93-4.56), HLA-DRB1*04 (OR, 1.40; CI, 1.02-1.93), HLA-DQB1*03 (OR, 2.86; CI, 1.57-5.21), HLA-A*33 (OR, 2.32; CI, 1.42-3.80), and HLA-B*44 (OR, 3.17; CI, 2.22-4.55) were associated with significantly increased risk of developing NP, whereas HLA-A*02 (OR, 0.64; CI, 0.47-0.87) conferred reduced risk and neither rs1799971 in OPRM1 (OR, 0.55; CI, 0.27-1.11) nor rs4680 in COMT (OR, 0.95; CI, 0.81-1.13) were significantly associated with NP. 29351172 2018
CUI: C0027796
Disease: Neuralgia
Neuralgia 		0.400 Biomarker phenotype BEFREE Endomorphins (EMs, including EM-1 and EM-2), the most effective and specific endogenous agonists of the MOR, exert more potent analgesia in acute and neuropathic pain than other opiates, such as morphine. 28848403 2017
CUI: C0027796
Disease: Neuralgia
Neuralgia 		0.400 Biomarker phenotype BEFREE Bivalent ligand that activates mu opioid receptor and antagonizes mGluR5 receptor reduces neuropathic pain in mice. 28891868 2017
CUI: C0027796
Disease: Neuralgia
Neuralgia 		0.400 AlteredExpression phenotype BEFREE Inhibition of DNMT3a catalytic activity with DNMT inhibitor RG108 significantly blocked the increase in methylation of the MOR promoter, and then upregulated MOR expression and attenuated thermal hyperalgesia in neuropathic pain mice. 29075135 2017
CUI: C0027796
Disease: Neuralgia
Neuralgia 		0.400 Biomarker phenotype BEFREE Blocking this increase also prevented the nerve injury-induced increase in DNA methylation in the promoter and 5'-untranslated region of the Oprm1 gene in the injured DRG, restored morphine or loperamide (a peripheral acting MOR preferring agonist) analgesic effects, and attenuated the development of their analgesic tolerance under neuropathic pain conditions. 28267064 2017
CUI: C0027796
Disease: Neuralgia
Neuralgia 		0.400 Biomarker phenotype BEFREE Mimicking SNL-induced DRG miR-143 downregulation through DRG microinjection of miR143 inhibitors in naive rats increased the expression of Dnmt3a and reduced the expression of <i>Oprm1</i> mRNA and MOR in injected DRG and produced neuropathic pain-like symptoms. 29170626 2017
CUI: C0027796
Disease: Neuralgia
Neuralgia 		0.400 GeneticVariation phenotype BEFREE Effect of naltrexone on neuropathic pain in mice locally transfected with the mutant μ-opioid receptor gene in spinal cord. 24866991 2015
CUI: C0027796
Disease: Neuralgia
Neuralgia 		0.400 AlteredExpression phenotype BEFREE Our present data suggested a model that miR-134 participated in CFA-induced inflammatory pain by balancing the expression of MOR1 in DRGs, which implied that miR-134 may be a potential therapeutic target for the treatment of neuropathic pain including inflammation. 22865422 2013
CUI: C0027796
Disease: Neuralgia
Neuralgia 		0.400 Biomarker phenotype CTD_human Pharmacological characterization and gene expression profiling of an L5/L6 spinal nerve ligation model for neuropathic pain in mice. 18400411 2008
CUI: C0027796
Disease: Neuralgia
Neuralgia 		0.400 Biomarker phenotype BEFREE To assess whether MOP-R phosphorylation occurs following endogenous opioid release, we induced chronic neuropathic pain by partial sciatic nerve ligation (pSNL), which caused a significant increase in MOR-P2-IR in the striatum. pSNL also induced signs of mu opioid receptor tolerance demonstrated by a rightward shift in the morphine dose response in the tail withdrawal assay and by a reduction in morphine conditioned place preference (CPP). 17467916 2007
CUI: C0027796
Disease: Neuralgia
Neuralgia 		0.400 Biomarker phenotype CTD_human Loss of peripheral morphine analgesia contributes to the reduced effectiveness of systemic morphine in neuropathic pain. 14718584 2004
CUI: C0027796
Disease: Neuralgia
Neuralgia 		0.400 AlteredExpression phenotype BEFREE Plasticity of MuOR gene expression may contribute to variations in clinical responses to opioid analgesics in clinical states such as neuropathic pain. 9366465 1997